-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Golden Minerals Completes Drilling Desierto, Argentina
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
Making the Most of a Long Weekend Without Leaving Town
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Paul Scribner on General Holdings Limited's Role as a Principal Investor in Complex, Cross-Border Opportunities
-
Best Gold IRA Rollover Companies 2026 Announced: How to Choose and Gold IRA Rollover Basics Explained in New Guide
-
Remergify and Ready Set Fund Grow Launch Municipal Opportunity Zone Framework to Modernize Core Public Utilities and Bridge the Divide Between Luxury Growth and Community Stability
-
CreditRiskMonitor Trade Contributors Use New Self-Serve Feature
-
Caldwell Expands Leadership Advisory With Launch of Caldwell Leadership Intelligence
-
neoseek Builds on a Decade of Engineering Expertise to Accelerate Global Expansion in Portable Charging
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Route1 Announces Issuance of Shares for Compensation
-
Modular Medical Secures Coverage Agreements with All Three of the Nation's Largest PBMs for Pivot Insulin Delivery System
-
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -
SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARI™ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 being held in Paris, France, from September 17-20th.
Details of the abstract are as follows:
Abstract Title: Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris - Results from the STAR-1 Phase 3 Study
Abstract Number: P3243
The full abstract will be released on Tuesday, September 16, 2025, at 10:00pm (PST). For more information about the EADV Congress 2025, please visit https://eadv.org/congress/
Click here to view the EADV abstract.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize OTC dermatology products; the anticipated benefits of the strategic shift; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; risks that clinical trials may not be predictive of real-world results or of results of subsequent clinical trials; risks that current clinical trials will lead to further product development by the Company; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Dermata Investors:
Cliff Mastricola
Investor Relations
[email protected]
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
N.Mitchell--AT